AnaCardio Publishes AC01 Heart Failure Study in The Lancet
STOCKHOLM, Sweden, June 25, 2026 AnaCardio announced that results from its Phase 1b/2a GOAL-HF1 clinical trial evaluating AC01, a...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
STOCKHOLM, Sweden, June 25, 2026 AnaCardio announced that results from its Phase 1b/2a GOAL-HF1 clinical trial evaluating AC01, a...
